第五届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况： 证券代码：603222 证券简称：济民医疗 公告编号：2023-056 济民健康管理股份有限公司 公司拟续聘天健会计师事务所（特殊普通合伙）为公司2023年度审计机构和 内部控制审计机构。 济民健康管理股份有限公司（以下简称"公司"）第五届董事会第八次会议于 2023 年 9 月 20 日以通讯表决方式召开，会议通知于 2023 年 9 月 14 日通过电 话、邮件及书面形式发出，本次会议由董事李丽莎女士主持，应出席董事 7 名， 实际出席董事 7 名。会议的召集，召开符合《公司法》和《公司章程》的有关规 定，会议合法有效。 二、董事会会议审议情况： 经过与会董事认真审议，形成如下决议： （一）以 4 票同意，0 票反对，0 票弃权，3 票回避，审议通过《关于调整公 司独立董事津贴的议案》。 本议案尚需提交公司 2023 年第二次临时股东大会审议。 公司《调整公司独立董事津贴的公告》详见 2023 年 9 月 21 ...

证券代码：603222 证券简称：济民医疗 公告编号：2023-057 济民健康管理股份有限公司 调整公司独立董事津贴的公告 济民健康管理股份有限公司董事会 2023 年 9 月 21 日 根据中国证监会《上市公司独立董事规则》等法律法规的要求及《公司章 程》的相关规定，为更好地实现公司战略发展目标，有效调动公司独立董事的 工作积极性，综合考虑独立董事为公司规范运作、内控体系建设和可持续发展 做出的重要贡献，同时参考行业薪酬水平、地区经济发展状况以及公司实际情 况，建议公司将独立董事年度津贴由 7 万元（税前）调整至 9 万元（税前）， 所涉及的个人所得税均由公司统一代扣代缴，自股东大会审议通过之日起实 施。 二、独立董事意见 公司独立董事对本事项发表了明确同意的独立意见：公司此次调整独立董 事津贴符合公司实际经营情况，有利于调动独立董事的工作积极性，符合公司 长远发展的需要。本次事项决策程序符合《公司法》、《公司章程》等有关规 定，不存在损害公司及股东利益的情形。我们同意将该议案提交公司 2023 年 第二次临时股东大会审议。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述 ...

证券代码：603222 证券简称：济民医疗 公告编号：2023-059 济民健康管理股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●济民健康管理股份有限公司（以下简称"公司"）拟续聘天健会计师事务 所（特殊普通合伙）（以下简称"天健"）为公司2023年度审计机构和内部控制 审计机构。 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2011 7 月 组织形式 | 年 | 18 | 日 | | | 特殊普通合伙 | | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 | | | | 128 | 号 | | | | 首席合伙人 | 胡少先 上年末合伙人数量 | | | | | | 225 | 人 | | 上年末执业人员数量 | 注册会 ...

证券代码：603222 证券简称：济民医疗 公告编号：2023-060 济民健康管理股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年第二次临时股东大会 召开的日期时间：2023 年 10 月 18 日 14 点 30 分 召开地点：浙江省台州市黄岩北院路 888 号行政楼四楼会议室 (五) 网络投票的系统、起止日期和投票时间。 (七) 涉及公开征集股东投票权 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 10 月 18 日 股东大会召开日期：2023年10月18日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 至 2023 年 10 月 18 日 采用上海证券交易所网络投 ...

证券代码：603222 证券简称：济民医疗 公告编号：2023-055 济民健康管理股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●回购方案的实施情况：2023 年 8 月，公司通过集中竞价交易方式已累计 回购股份 5,564,800 股，占公司总股本的比例为 1.036%，购买的最高价为 9.79 元/股，最低价为 9.21 元/股，已支付的总金额为 52,283,815 元（不含交易费 用）。 一、回购的基本情况 次回购符合相关法律法规的规定及公司既定的回购股份方案。 三、其他说明 公司后续将根据市场情况在回购实施期限内继续实施本次回购计划，并根 据相关法律法规和规范性文件的要求及时履行信息披露义务。敬请广大投资者 注意投资风险。 特此公告。 济民健康管理股份有限公司董事会 2023 年 9 月 2 日 济民健康管理股份有限公司（以下简称"公司"）于 2023 年 7 月 24 日召 开第五届董事会第七次会议，审议通过了《关于以集中竞价交易方式回 ...

证券代码：603222 证券简称：济民医疗 公告编号：2023-054 截至 2023 年 8 月 25 日，公司通过集中竞价交易方式累计回购股份 5,564,800 股，占公司总股本的比例为 1.036%，与上次披露数相比增加 0.969%， 购买的最高价为 9.79 元/股，最低价为 9.21 元/股，已支付的总金额为 52,283,815 元（不含交易费用）。 济民健康管理股份有限公司 关于以集中竞价交易方式回购公司股份比例达到总 股本 1%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●回购方案的实施情况：截至 2023 年 8 月 25 日，公司通过集中竞价交易 方式已累计回购股份 5,564,800 股，占公司总股本的比例为 1.036%，已支付的 总金额为 52,283,815 元（不含交易费用）。 一、回购的基本情况 济民健康管理股份有限公司（以下简称"公司"）于 2023 年 7 月 24 日召 开第五届董事会第七次会议，审议通过了《关于以集中竞价交易方式回购公司 股份方案的 ...

证券代码：603222 证券简称：济民医疗 公告编号：2023-052 公司将严格按照相关规定实施股份回购并及时履行信息披露义务。敬请广 大投资者注意投资风险。 特此公告。 济民健康管理股份有限公司董事会 2023年8月12日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 济民健康管理股份有限公司（以下简称"公司"）于 2023 年 7 月 24 日召 开第五届董事会第七次会议，审议通过了《关于以集中竞价交易方式回购公司 股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购公司股份 用于后续实施员工持股计划，回购价格不超过人民币 12.50 元/股（含），回购 资金总额不低于 6,000 万元（含）且不超过 12,000 万元（含），回购期限为自 董事会审议通过回购股份方案之日起不超过 12 个月。具体内容详见公司于 2023 年 7 月 25 日在上海证券交易所网站（www.sse.com.cn）披露的《关于以集中竞 价交易方式回购公司股份方案的公告》（公告编号：2023-049）。 根据《上市公司股份回购规则》及 ...

Financial Performance - The company achieved total operating revenue of RMB 444.34 million in the first half of 2023, a year-on-year increase of 1.64%[22] - Net profit attributable to shareholders was RMB 39.23 million, representing a decrease of 39.50% compared to the same period last year[22] - The net cash flow from operating activities was RMB 63.42 million, down 42.80% year-on-year[22] - Basic earnings per share decreased by 50.00% to RMB 0.07 compared to the same period last year[24] - The weighted average return on net assets fell by 2.84 percentage points to 2.27%[24] - The company's net profit attributable to shareholders decreased by 39.50% year-on-year, dropping from 52.38 million RMB to 8.80 million RMB, primarily due to a 73.33% decline in the export volume of safety syringes[25] - The net profit excluding non-recurring gains and losses fell by 29.20% compared to the same period last year[25] - The company achieved total revenue of 444.34 million yuan, a year-on-year increase of 1.64%, with the medical services segment growing by 52.07% to 177.04 million yuan[50] - The company reported a total profit of RMB 56,384,908.21 for the first half of 2023, down 24.4% from RMB 74,608,543.29 in the previous year[132] - The company’s total comprehensive income for the first half of 2023 was RMB 58,064,709.24, slightly down from RMB 59,520,766.64 in the first half of 2022[133] Revenue Segmentation - The medical services segment generated revenue of RMB 17.70 million, up 52.07% year-on-year[24] - The medical device segment reported revenue of RMB 12.81 million, a decline of 34.71% compared to the previous year[24] - The large-volume infusion segment's revenue was RMB 13.62 million, reflecting a growth of 10.63% year-on-year[24] - The medical services segment's revenue share increased from 26.63% to 39.84%, indicating its growing importance to the company's overall income[52] - The Boao International Hospital generated revenue of 106.70 million yuan, a 53.40% increase year-on-year, and achieved profitability with a net profit of 28.27 million yuan[53] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2.58 billion, a decrease of 5.02% from the end of the previous year[22] - Net assets attributable to shareholders increased by 1.96% to RMB 1.74 billion at the end of the reporting period[22] - Total liabilities decreased from ¥939,637,779.38 to ¥756,027,258.76, a reduction of about 19.5%[124] - Current liabilities decreased from ¥584,082,941.98 to ¥448,676,070.31, a decrease of approximately 23.2%[124] - Non-current liabilities decreased from ¥355,554,837.40 to ¥307,351,188.45, a decline of about 13.5%[128] Cash Flow - The net cash flow from operating activities decreased by 42.80% to CNY 63.42 million due to a decline in cash received from sales[62] - Cash and cash equivalents decreased by 62.18% to CNY 245.56 million, primarily due to idle funds being invested in financial products[64] - Cash received from sales of goods and services was CNY 444,207,397.34, down from CNY 507,417,708.28 in the first half of 2022[138] - Cash paid for purchasing goods and services was CNY 162,752,534.01, a decrease from CNY 176,210,317.99 in the same period last year[138] Strategic Initiatives - The company plans to achieve full production capacity of 250 million units for pre-filled catheter flushing devices by the second half of 2023[40] - The company is actively participating in centralized procurement to enhance sales scale and market share for its products[55] - The company aims to enhance its overall medical technology service level through collaboration with international expert teams and the introduction of cutting-edge medical technologies[33] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[145] Environmental and Compliance - The company reported a total wastewater discharge of 12.67 tons for the first half of the year, with an average concentration of 180 mg/L for COD and ammonia nitrogen[84] - The company has a wastewater treatment facility with a capacity of 80 tons/day and an acid-base neutralization facility with a capacity of 1440 tons/day, both operating normally and meeting environmental standards[85] - The company has a comprehensive emergency response plan for environmental pollution incidents, with a drill conducted on May 19, 2023[88] - The company conducts real-time monitoring of wastewater, updating data every hour[88] Shareholder Information - The company has a total of 537,237,415 shares outstanding after a private placement of 60,196,560 shares at a price of 8.14 RMB per share[104] - The number of ordinary shareholders reached 24,844 by the end of the reporting period[108] - The top shareholder, Shuangge Group Co., Ltd., holds 127,983,520 shares, accounting for 23.82% of the total shares[110] - The report indicates that the company has a total of 77,277,020 shares held by the actual controller's family, amounting to 14.38% of the total share capital[112] Legal and Risk Management - The company is currently in litigation to recover CNY 105.76 million from Shaopin due to a breach of contract[59] - The company faces significant risks including policy risks, quality control risks, and market competition risks in the pharmaceutical industry[73] - The company emphasizes compliance and quality risk management while pursuing steady growth in the healthcare service sector[74] - The company is exposed to internationalization risks, including unfamiliarity with overseas markets and trade protectionism[74] Research and Development - Research and development expenses were RMB 13,593,441.72, a decrease of 17.5% compared to RMB 16,520,378.51 in the first half of 2022[131] - The company has allocated resources for research and development, focusing on innovative technologies to enhance product offerings[145]

证券代码：603222 证券简称：济民医疗 公告编号： 2023-033 济民健康管理股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 05 月 23 日(星期二) 至 05 月 29 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investment@chimin.cn 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 济民健康管理股份有限公司（以下简称"公司"）已于 2023 年 4 月 20 日发 布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经 营成果、财务状况，公司计划于 2023 年 05 月 30 日下午 13:00-14:00 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥222,593,735.45, a decrease of 22.03% compared to the same period last year[2] - Net profit attributable to shareholders was ¥33,728,551.42, down 52.28% year-on-year[2] - Basic earnings per share decreased by 60.00% to ¥0.06[2] - The net cash flow from operating activities was ¥33,603,831.24, representing a decline of 69.57%[2] - The decline in net profit was primarily due to a decrease in the export volume of safety syringes[5] - Total operating costs for Q1 2023 were CNY 180,569,449.78, down from CNY 210,223,759.68 in Q1 2022, representing a reduction of approximately 14.1%[15] - The total comprehensive income for Q1 2023 was CNY 44,344,907.54, compared to CNY 72,996,128.67 in Q1 2022, indicating a decrease of 39.2%[16] - The company reported a decrease in sales revenue from CNY 319,525,005.26 in Q1 2022 to CNY 218,159,958.69 in Q1 2023, a decline of 31.7%[17] - The financial expenses for Q1 2023 were CNY 5,048,661.07, down from CNY 7,615,572.35 in Q1 2022, showing a decrease of 33.4%[15] - The company recorded a net investment loss of CNY -3,575.85 in Q1 2023, compared to a profit of CNY 9,849,463.05 in Q1 2022[15] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,633,081,701.86, a decrease of 2.98% from the end of the previous year[3] - The company's total assets as of March 31, 2023, amounted to CNY 2,633,081,701.86, down from CNY 2,714,060,425.59 at the end of 2022, reflecting a decrease of about 3%[12] - The total current assets decreased to CNY 970,900,978.68 from CNY 1,046,444,861.54, representing a decline of approximately 7%[10] - The total non-current assets slightly decreased to CNY 1,662,180,723.18 from CNY 1,667,615,564.05, indicating a reduction of about 0.3%[11] - The company's total liabilities decreased to CNY 814,314,148.11 from CNY 939,637,779.38, a decline of approximately 13%[12] - The total equity attributable to shareholders increased to CNY 1,741,485,932.78 from CNY 1,706,949,742.99, reflecting an increase of about 2%[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,665[6] - The largest shareholder, Shuangge Group Co., Ltd., held 127,983,520 shares, accounting for 23.82% of the total shares[7] - The company completed the registration of 60,196,560 new shares from a non-public offering, increasing the total number of shares to 537,237,415[9] - The company plans to implement a stock option incentive plan for 2023, pending approval from the shareholders' meeting[9] Cash Flow - Cash and cash equivalents decreased significantly to CNY 311,618,920.40 from CNY 649,306,426.64, a drop of approximately 52%[10] - The net cash flow from operating activities for Q1 2023 was CNY 33,603,831.24, a decline of 69.6% from CNY 110,443,571.72 in Q1 2022[18] - The company reported a net cash outflow from investing activities of CNY -279,014,339.17 in Q1 2023, compared to CNY -78,419,068.25 in Q1 2022[18] - Total cash inflow from financing activities was $99,422,400, a decrease from $101,573,975.50 in the previous period[19] - Cash outflow from financing activities totaled $187,695,547.99, compared to $87,625,913.01 previously, indicating a significant increase[19] - Net cash flow from financing activities was -$88,273,147.99, contrasting with a positive $13,948,062.49 in the prior period[19] - The net increase in cash and cash equivalents was -$334,682,506.24, compared to an increase of $45,235,910.94 previously[19] - The ending balance of cash and cash equivalents was $301,043,420.40, down from $306,438,419.83 in the previous period[19] Research and Development - Research and development expenses decreased to CNY 6,259,247.57 in Q1 2023 from CNY 7,845,210.89 in Q1 2022, reflecting a reduction of 20.2%[15] Accounting Standards - The company has not adopted new accounting standards or interpretations for the current year[19]